Eli Lil­ly touts PhI­II suc­cess for Taltz as ri­val No­var­tis stays well out front in crowd­ed im­munol­o­gy race

The chess pieces are mov­ing again in the block­buster mar­ket­ing game of im­munol­o­gy drugs.

This morn­ing it’s Eli Lil­ly’s $LLY turn to make a move, spot­light­ing pos­i­tive Phase III re­sults for its block­buster hope­ful Taltz (ix­ek­izum­ab) for anky­los­ing spondyli­tis.

All we have is the top-line re­sult against a place­bo, though, in a field where No­var­tis $NVS has con­tin­ued to ex­pand on longterm out­comes for pa­tients with its first-to-mar­ket block­buster Cosen­tyx. Lil­ly boasts that Taltz scored on the pri­ma­ry and all the sec­on­daries in the study as it preps new reg­u­la­to­ry fil­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER